Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Taxotere With Concurrent Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
NCT00318903Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2002
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, docetaxel in esophageal cancer, sponsored by University of Alabama at Birmingham. Started Jan 2002; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabdocetaxel
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00318903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00318903.